Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
Innovent Biologics announces the presentation of nearly 10 clinical data studies of its novel oncology molecules at ESMO Asia Congress 2024, scheduled for December 6-8 in Singapore. The highlight includes an oral presentation of updated Phase 1 results for their TOPO1i CLDN18.2 ADC (IBI343) in treating pancreatic cancer. The presentations encompass various cancer treatments, including studies on colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer. The data demonstrates encouraging efficacy and safety profiles, particularly for IBI343 in pancreatic cancer treatment, showcasing the company's progress in IO+ADC therapeutic development.
Innovent Biologics annuncia la presentazione di quasi 10 studi clinici sui suoi nuovi molecole oncologiche al Congresso ESMO Asia 2024, che si terrà dal 6 all'8 dicembre a Singapore. Il punto saliente comprende una presentazione orale dei risultati aggiornati della Fase 1 per il loro ADC TOPO1i CLDN18.2 (IBI343) nel trattamento del cancro pancreatico. Le presentazioni coprono vari trattamenti oncologici, inclusi studi sul cancro colorettale, carcinoma epatocellulare e cancro polmonare non a piccole cellule. I dati dimostrano profili di efficacia e sicurezza incoraggianti, in particolare per IBI343 nel trattamento del cancro pancreatico, evidenziando i progressi dell'azienda nello sviluppo terapeutico IO+ADC.
Innovent Biologics anuncia la presentación de casi 10 estudios de datos clínicos sobre sus nuevas moléculas de oncología en el Congreso ESMO Asia 2024, programado para el 6 al 8 de diciembre en Singapur. El punto destacado incluye una presentación oral de los resultados actualizados de la Fase 1 de su ADC TOPO1i CLDN18.2 (IBI343) en el tratamiento del cáncer de páncreas. Las presentaciones abarcan varios tratamientos contra el cáncer, incluidos estudios sobre cáncer colorrectal, carcinoma hepatocelular y cáncer de pulmón no microcítico. Los datos demuestran perfiles de eficacia y seguridad alentadores, particularmente para IBI343 en el tratamiento del cáncer pancreático, mostrando el progreso de la empresa en el desarrollo terapéutico IO+ADC.
Innovent Biologics는 2024년 12월 6일부터 8일까지 싱가포르에서 열리는 ESMO 아시아 컨그레스에서 자사의 새로운 온콜로지 분자에 대한 거의 10개의 임상 데이터 연구를 발표한다고 발표했습니다. 주요 내용은 췌장암 치료를 위한 그들의 TOPO1i CLDN18.2 ADC (IBI343)에 대한 업데이트된 1상 결과에 대한 구두 발표를 포함하고 있습니다. 발표는 대장암, 간세포암, 비소세포 폐암에 대한 연구를 포함한 다양한 암 치료를 포괄합니다. 데이터는 췌장암 치료에서 IBI343의 특히 고무적인 효능과 안전성 프로파일을 보여주며, IO+ADC 치료 개발에서 회사의 진전을 강조합니다.
Innovent Biologics annonce la présentation de près de 10 études de données cliniques sur ses nouvelles molécules en oncologie lors du Congrès ESMO Asia 2024, qui se déroulera du 6 au 8 décembre à Singapour. Le point fort inclut une présentation orale des résultats actualisés de la Phase 1 de leur ADC TOPO1i CLDN18.2 (IBI343) dans le traitement du cancer du pancréas. Les présentations englobent divers traitements contre le cancer, y compris des études sur le cancer colorectal, le carcinome hépatocellulaire et le cancer du poumon non à petites cellules. Les données montrent des profils d'efficacité et de sécurité encourageants, en particulier pour IBI343 dans le traitement du cancer du pancréas, mettant en avant les progrès de l'entreprise dans le développement thérapeutique IO+ADC.
Innovent Biologics kündigt die Präsentation von fast 10 klinischen Datestudien zu seinen neuen onkologischen Molekülen auf dem ESMO Asia Kongress 2024 an, der vom 6. bis 8. Dezember in Singapur stattfinden wird. Höhepunkt ist eine mündliche Präsentation der aktualisierten Ergebnisse der Phase 1 für ihr TOPO1i CLDN18.2 ADC (IBI343) zur Behandlung von Bauchspeicheldrüsenkrebs. Die Präsentationen umfassen verschiedene Krebsbehandlungen, einschließlich Studien zu darmkrebs, leberzellkarzinom und nicht-kleinzelligem Lungenkrebs. Die Daten zeigen ermutigende Wirksamkeits- und Sicherheitsprofile, insbesondere für IBI343 bei der Behandlung von Bauchspeicheldrüsenkrebs, und heben die Fortschritte des Unternehmens in der IO+ADC-Therapieentwicklung hervor.
- Phase 1 trial of IBI343 shows encouraging efficacy and good safety profile in pancreatic cancer treatment
- Company demonstrates advancement in multiple oncology programs across various cancer types
- Strong presence at major international conference with nearly 10 clinical data presentations
- None.
Details on the abstracts are listed below:
Mini Oral
Abstract Title: Anti-claudin18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients with advanced pancreatic ductal adenocarcinoma (PDAC): updated results from a Phase 1 study
Abstract No: 132MO
Session Type and Title: Mini Oral session: Gastrointestinal tumors
Presentation Time: 2024-12-07, 09:50-09:55
Presenter: Jian Zhang, Fudan University Shanghai Cancer Center, CN
Abstract Title: mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody in Locally Advanced MSS CRC (BASKETⅡ): A Prospective, Single-Arm, Open-Label, Phase 2 Study
Abstract No: 74MO
Session Type and Title: Mini Oral session: Gastrointestinal tumors
Presentation Time: 2024-12-07, 10:20-10:25
Presenter: Jun Huang, The Sixth Affiliated Hospital, Sun Yat-sen University, CN
Posters
Abstract Title: Anlotinib plus Sintilimab as First-line Treatment for Patients with Advanced Colorectal Cancer (APICAL-CRC): an Open-Label, Single-arm, Phase 2 study
Abstract No: 75P
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Zhan Wang, Shanghai Changzheng Hospital, The Second Affiliated Hospital of Naval Medical University, CN
Abstract Title: A single-arm, multicenter, Phase 2 study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203)
Abstract No: 137P
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Gaojun Teng, Zhongda Hospital, Southeast University, CN
Abstract Title: FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: a single-arm, Phase 2 study
Abstract No: 207P
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Bin Liang/ Zizhuo Wang, Union Hospital Tongji Medical College Huazhong University of Science and Technology, CN
Abstract Title: Updated results from Phase 2 study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced hepatocellular carcinoma (HCC)
Abstract No: 214P
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Haibin Zhang, Eastern Hepatobiliary Surgery Hospital, Third Affiliated Hospital of Naval Medical University, CN
Abstract Title: Anlotinib Combined with Sintilimab Versus Chemotherapy Combined with Immunotherapy in Perioperative NSCLC: A Phase 2 Study
Abstract No: 599P
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Tianqing Chu, Shanghai Chest Hospital, Shanghai Jiao Tong University,
Trial in Progress abstracts (TiP)
Abstract Title: A randomized, controlled, multicenter Phase 3 study of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer: Trial in Progress
Abstract No.: 119TiP
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Ruihua Xu, Sun Yat-sen University Cancer Center, CN
Abstract Title: Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy with Cryoablation in the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Abstract No.: 722TiP
Session Type and Title: Poster Display session
Presentation Time: 2024-12-07, 17:50-18:45
Presenter: Zhiqiang Gao, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine,
Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present and share a robust set of clinical data at EAMO Asia 2024. Notably, we are highlighting the breakthrough potential for our TOPO1i CLDN18.2 ADC (IBI343) in pancreatic cancer, a global difficult-to-treat cancer. Consistent with the preliminary signal observed in small patient size, the data in dose expansion stage demonstrated encouraging efficacy and good safety, which reinforced our confidence in advancing its development. Given unique design of Fc-silent antibody, combined with stable linker and potent extecan payload, IBI343 pioneered in the exploration of CLDN18.2 ADC agents for PDAC treatment. As one of the few biopharmaceutical companies with both advanced technology platforms and a robust pipeline in "IO+ADC" areas, Innovent remains dedicated to transforming cancer treatment by delivering innovative, effective, and safe therapeutic options for doctors and patients."
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 5 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Statement: |
（1）Innovent does not recommend the use of any unapproved drug (s)/indication (s). |
（2）Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) were developed by Eli Lilly and Company. |
Forward-looking statement
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.
The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.
View original content:https://www.prnewswire.com/news-releases/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024-302314905.html
SOURCE Innovent Biologics
FAQ
What clinical data will Innovent present at ESMO Asia 2024?
What are the key findings of Innovent's IBI343 Phase 1 study for pancreatic cancer?
When and where will Innovent present its clinical data at ESMO Asia 2024?
